ÅǸ޴º
¹øÈ£ | ±¸ºÐ | Á¦¸ñ |
---|---|---|
313 | (±¹¿Ü)SCI | PB101, a VEGF- and PlGF-targeting decoy protein, enhances antitumor immunity and suppresses tumor progression and metastasis |
312 | (±¹¿Ü)SCI | PB101, a VEGF- and PlGF-targeting decoy protein, enhances antitumor immunity and suppresses tumor progression and metastasis |
311 | (±¹¿Ü)SCI | Systemic Delivery of a STING Agonist-Loaded PositivelyCharged Liposome Selectively Targets Tumor ImmuneMicroenvironment and Suppresses Tumor Angiogenesis |
310 | (±¹¿Ü)SCI | Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial |
309 | (±¹¿Ü)SCI | Thyroid Dysfunction After Atezolizumab and Bevacizumab is Associated with Favorable Outcomes in Hepatocellular Carcinoma |
308 | (±¹¿Ü)SCI | Multifunctional porous microspheres encapsulating oncolytic bacterial spores and their potential for cancer immunotherapy |
307 | (±¹¿Ü)SCI | ARID1A Mutation from Targeted NGS Predicts Primary Resistance to Gemcitabine and Cisplatin Chemotherapy in Advanced Biliary Tract Cancer |
306 | (±¹¿Ü)SCI | ARID1A Mutation from Targeted NGS Predicts Primary Resistance to Gemcitabine and Cisplatin Chemotherapy in Advanced Biliary Tract Cancer |
305 | (±¹¿Ü)SCI | High Levels of Antidrug Antibodies Against Atezolizumab as a Predictive Marker for Clinical Outcomes in Patients With Hepatocellular Carcinoma?Reply |
304 | (±¹¿Ü)SCI | High Levels of Antidrug Antibodies Against Atezolizumab as a Predictive Marker for Clinical Outcomes in Patients With Hepatocellular Carcinoma?Reply |
Copyright ¨Ï chamc, All rights reserved.